Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial

MLA

Arif Manji, et al. “Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial.” Cancers; Volume 14; Issue 12; Pages: 2985, June 2022. EBSCOhost, https://doi.org/10.3390/cancers14122985.

APA

Arif Manji, Yvan Samson, Rebecca J. Deyell, Donna L. Johnston, Victor A. Lewis, Alexandra P. Zorzi, Jason N. Berman, Kathy Brodeur-Robb, Ellen Morrison, Lynn Kee, Sushil Kumar, Sylvain Baruchel, James A. Whitlock, & Daniel A. Morgenstern. (2022). Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial. Cancers; Volume 14; Issue 12; Pages: 2985. https://doi.org/10.3390/cancers14122985

Chicago

Arif Manji, Yvan Samson, Rebecca J. Deyell, Donna L. Johnston, Victor A. Lewis, Alexandra P. Zorzi, Jason N. Berman, et al. 2022. “Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial.” Cancers; Volume 14; Issue 12; Pages: 2985, June. doi:10.3390/cancers14122985.